These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 15375003)

  • 1. International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?
    Belardelli F; Ferrantini M; Parmiani G; Schlom J; Garaci E
    Cancer Res; 2004 Sep; 64(18):6827-30. PubMed ID: 15375003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International meeting "Immunotherapy of cancer: challenges and needs".
    Ferrantini M; Capone I; Marincola FM; Parmiani G; Belardelli F
    Cancer Immunol Immunother; 2007 Apr; 56(4):581-5. PubMed ID: 17131119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
    Moschella F; Proietti E; Capone I; Belardelli F
    Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.
    Gatti-Mays ME; Redman JM; Collins JM; Bilusic M
    Hum Vaccin Immunother; 2017 Nov; 13(11):2561-2574. PubMed ID: 28857666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
    Banday AH; Jeelani S; Hruby VJ
    Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the use of dendritic cells and new adjuvants for the development of therapeutic vaccines.
    Santini SM; Belardelli F
    Stem Cells; 2003; 21(4):495-505. PubMed ID: 12832702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status and future prospects of peptide-based cancer vaccines.
    Wada S; Yada E; Ohtake J; Fujimoto Y; Uchiyama H; Yoshida S; Sasada T
    Immunotherapy; 2016 Nov; 8(11):1321-1333. PubMed ID: 27993087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer vaccines: preclinical studies and novel strategies.
    Palena C; Abrams SI; Schlom J; Hodge JW
    Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Various ways to improve whole cancer cell vaccines.
    Cicchelero L; de Rooster H; Sanders NN
    Expert Rev Vaccines; 2014 Jun; 13(6):721-35. PubMed ID: 24758597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in Therapeutic Cancer Vaccines.
    Wong KK; Li WA; Mooney DJ; Dranoff G
    Adv Immunol; 2016; 130():191-249. PubMed ID: 26923002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines.
    Schijns V; Tartour E; Michalek J; Stathopoulos A; DobrovolskienÄ— NT; Strioga MM
    Cytotherapy; 2014 Apr; 16(4):427-39. PubMed ID: 24280238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide-based vaccines for cancer therapy.
    Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
    Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of type I interferon in inducing a protective immune response: perspectives for clinical applications.
    Rizza P; Moretti F; Capone I; Belardelli F
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):195-201. PubMed ID: 25466627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer vaccines: a critical review on clinical impact.
    Bitton RJ
    Curr Opin Mol Ther; 2004 Feb; 6(1):17-26. PubMed ID: 15011777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of clinical trials for therapeutic cancer vaccines development.
    Mackiewicz J; Mackiewicz A
    Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokines in cancer therapy.
    Parmiani G; Rivoltini L; Andreola G; Carrabba M
    Immunol Lett; 2000 Sep; 74(1):41-4. PubMed ID: 10996626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.